Acute Leukemias - Republican Scientific Medical Library
Acute Leukemias - Republican Scientific Medical Library
Acute Leukemias - Republican Scientific Medical Library
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
a References 245<br />
23. Jeha S, Gandhi V, Chan KW, et al. (2004) Clofarabine, a novel nucleoside<br />
analog, is active in pediatric patients with advanced leukemia.<br />
Blood 103(3):784–789<br />
24. Jeha S, Razzouk BI, Rytting ME, et al. (2004) Phase II trials of<br />
clofarabine in relapsed or refractory pediatric leukemia. Blood<br />
104:196a<br />
25. Kantarjian HM, Gandhi V, Kozuch P, et al. (2003) Phase I clinical and<br />
pharmacology study of clofarabine in patients with solid and<br />
hematologic cancers. J Clin Oncol 21:1167–1173<br />
26. Kantarjian H, Gandhi V, Cortes J, et al. (2003) Phase 2 clinical and<br />
pharmacologic study of clofarabine in patients with refractory or<br />
relapsed acute leukemia. Blood 102:2379–2386<br />
27. Santini V, Kantarjian HM, Issa J-P (2001) Changes in DNA methylation<br />
in neoplasia: Pathophysiology and therapeutic implications.<br />
Ann Intern Med 134:573–586<br />
28. Garcia-Manero G, Bueso-Ramos C, Daniel J, et al. (2002) DNA<br />
methylation patterns at relapse in adult acute lymphocytic leukemia.<br />
Clin Cancer Res 8:1897–1903<br />
29. Garcia-Manero G, Daniel J, Smith TL, et al. (2002) DNA methylation<br />
of multiple promoter-associated CpG islands in adult acute lymphocytic<br />
leukemia. Clin Cancer Res 8:2217–2224<br />
30. Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, et al. (2004) Promoter<br />
hypermethylation of cancer-related genes: A strong independent<br />
prognostic factor in acute lymphoblastic leukemia.<br />
Blood 104:2492–2498<br />
31. Shen L, Toyota M, Kondo Y, et al. (2003) Aberrant DNA methylation<br />
of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic<br />
impact in adult acute lymphocytic leukemia. Blood 101:<br />
4131–4136<br />
32. Faderl S, Kantarjian HM, Thomas DA, et al. (2000) Outcome of Philadelphia<br />
chromosome-positive adult acute lymphoblastic leukemia.<br />
Leuk Lymphoma 36:263–273<br />
33. Thomas DA, Faderl S, Cortes J, et al. (2004) Treatment of Philadelphia<br />
chromosome-positive acute lymphocytic leukemia with hyper-CVAD<br />
and imatinib mesylate. Blood 103:4396–4407<br />
34. Thomas DA, Faderl S, Cortes J, et al. (2004) Update of the Hyper-<br />
CVAD and imatinib mesylate regimen in Philadelphia (Ph) positive<br />
acute lymphocytic leukemia (ALL). Blood 104:748a<br />
35. Towatari M, Yanada M, Usui N, et al. (2004) Combination of intensive<br />
chemotherapy and imatinib can rapidly induce high-quality<br />
complete remission for a majority of patients with newly diagnosed<br />
BCR-ABL-positive acute lymphoblastic leukemia. Blood<br />
104:3507–3512<br />
36. Ottmann OG, Wassmann B, Pfeifer H, et al. (2004) Imatinib given<br />
concurrently with induction chemotherapy is superior to imatinib<br />
subsequent to induction and consolidation in newly diagnosed<br />
Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).<br />
Blood 104:197a<br />
37. Giles F, Kantarjian H, Wassmann B, et al. (2004) A phase I/II study of<br />
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, on a continuous<br />
daily dosing schedule in adult patients (pts) with imatinib-resistant<br />
advanced phase chronic myeloid leukemia (CML)<br />
or relapsed/refractory Philadelphia chromosome (Ph+) acute lymphoblastic<br />
leukemia (ALL). Blood 104:10a<br />
38. Gögbuget N, Hoelzer D (2004) Treatment with monoclonal antibodies<br />
in acute lymphoblastic leukemia: Current knowledge<br />
and future prospects. Ann Hematol 83:201–205<br />
39. Thomas DA, Cortes J, O’Brien SM, et al. (2000) Significance of CD20<br />
positivity in de novo acute lymphocytic leukemia (ALL). Blood<br />
96:109a<br />
40. Thomas DA, Cortes J, Faderl S, et al. (2004) Outcome with the Hyper-CVAD<br />
and rituximab regimen in Burkitt (BL) and Burkitt-like<br />
(BLL) leukemia/lymphoma. Blood 104:901a<br />
41. Ozsahin H, Fluss J, McLin V, et al. (2003) Rituximab with interleukin-2<br />
after autologous bone marrow transplantation for acute<br />
lymphocytic leukemia in second remission. Med Pediatr Oncol<br />
38:300–301<br />
42. Tibes R, Keating MJ, Ferrajoli A, et al. (2006) Activity of alemtuzumab<br />
in patients with CD52-positive acute leukemia. Cancer 106:<br />
2645–2651<br />
43. Grossbard ML, Freedman AS, Ritz J, et al. (1992) Serotherapy of Bcell<br />
neoplasms with anti-B4-blocked ricin: A phase I trial of daily<br />
bolus infusion. Blood 79:576–585<br />
44. Szatrowski TP, Dodge RK, Reynolds C, et al. (2003) Lineage specific<br />
treatment of adult patients with acute lymphoblastic leukemia in<br />
first remission with anti-B4-blocked ricin or high-dose cytarabine:<br />
Cancer and Leukemia Group B study 9311. Cancer 97:1471–1480<br />
45. Graham ML (2003) Pegaspargase: A review of clinical studies. Adv<br />
Drug Delivery Rev 55:1293–1302<br />
46. Abshire TC, Pollock BH, Billett AL, et al. (2000) Weekly polyethylene<br />
glycol conjugated L-asparaginase compared with biweekly dosing<br />
produces superior induction remission rates in childhood relapsed<br />
acute lymphoblastic leukemia: A pediatric oncology group<br />
study. Blood 96:1709–1715<br />
47. Avramis VI, Sencer S, Periclou AP, et al. (2002) A randomized comparison<br />
of native Escherichia coli asparaginase and polyethylene<br />
glycol conjugated asparaginase for treatment of children with<br />
newly diagnosed standard-risk acute lymphoblastic leukemia:<br />
A Children’s Cancer Group study. Blood 99:1986–1994<br />
48. Hawkins D, Park JR, Thomson BG, et al. (2004) Asparaginase pharmacokinetics<br />
after intensive polyethylene glycol-conjugated L-asparaginase<br />
therapy for children with relapsed acute lymphoblastic<br />
leukemia. Clin Cancer Res 10:5335–5341<br />
49. Furman RR, Gandhi V, Bennett JC, et al. (2004) Intravenous forodesine<br />
(BCX-1777), a novel purine nucleoside phosphorylase<br />
(PNP) inhibitor, demonstrates clinical activity in phase I/II studies<br />
in patients with B-cell acute lymphoblastic leukemia. Blood<br />
104:750a<br />
50. Duvic M, Foss FM, Olsen EA, et al. (2004) Intravenous forodesine<br />
(BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor,<br />
demonstrates clinical activity in patients with refractory<br />
cutaneous T-cell lymphoma. Blood 104:683a<br />
51. Pui CH, Relling MV, Evans WE (2003) Role of pharmacogenomics<br />
and pharmacodynamics in the treatment of acute lymphoblastic<br />
leukemia. Best Pract Res Clin Haematol 15:741–756<br />
52. Krajinovic M, Costea I, Chiasson S (2002) Polymorphism of the thymidylate<br />
synthas gene and outcome of acute lymphoblastic leukemia.<br />
Lancet 359:1033–1034<br />
53. Ulrich CM, Yasui Y, Storb R, et al. (2001) Pharmacogenetics of<br />
methotrexate: Toxicity among marrow transplantation patients<br />
varies with the methylenetetrahydrofolate reductase C677T polymorphism.<br />
Blood 98:231–234<br />
54. Taub JW, Matherly LH, Ravindranath Y, et al. (2002) Polymorphisms<br />
in methylenetetrahydrofolate reductase and methotrexate sensi